Like Gilead, Ab­b­Vie gets its ten­ta­cles in­to pact with Ten­tar­ix

The oc­topi at Ten­tar­ix Bio­ther­a­peu­tics are cel­e­brat­ing this morn­ing.

Ab­b­Vie plans to pay $64 mil­lion up­front for two pro­grams out of the San Diego biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER